KatieB 310 Report post Posted January 28 The Canadian Cancer Survivor Network (CCSN), along with several other patient groups, have created a document for a submission to the pan Canadian Oncology Drug Review (pCODR). The submission is for a targeted therapy for cancers that are TRK Gene Fusion Positive and this includes several cancers including: thyroid, sarcoma, colorectal, lung and several paediatric cancers. TRK gene fusion positive cancers, simply put, is rare in common cancers but common in rare cancers. The CCSN is requesting input from patients or their caregivers on their perspective on this new targeted therapy, latrotectinib, that was recently approved by the FDA. Your input will help patients in Canada! Please participate in this 5-minute survey. Larotrectinib survey for TRK Gene Fusion-positive cancers: https://www.surveymonkey.com/r/ZNHFWKF Quote Share this post Link to post Share on other sites
